Truist Securities stays Buy on Terns Pharmaceuticals (TERN) as Merck acquires 'for a steal'
Tweet Send to a Friend
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $56.00 price target on Terns Pharmaceuticals (NASDAQ: TERN)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
